BPC-157 Dosage, half-life & reference guide
Also known as Body Protection Compound 157 · BPC157
A peptide derived from a protective protein in your stomach. In animal studies it speeds the repair of tendons, ligaments, muscle and gut lining, and it works partly by growing new blood vessels.
- Studied range
- 200–500 mcg
- How often
- 1–2× daily
- Half-life
- ~4–6 hours
- Evidence
- ●
●●Emerging - Routes
- SubQ, IM +1
Studied in research — not a recommendation.
How it works.
Synthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining.
Commonly reported: Faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots.
Half-life & active level
The half-life of BPC-157 is ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes).
Here's how a typical BPC-157 schedule plays out over 48 hours (one-compartment estimate).
An estimate from the half-life above, not a measurement. See your own curve build live in the half-life calculator.
Where BPC-157 works.
Gut
In animals. Its developers describe it as coming from a protein in human stomach juice, and in rats it helped injuries of the stomach and gut lining heal.
Joints & tendons
In animals. In a rat study where the Achilles tendon was cut from the heel bone, treated tendons healed stronger and better organized over the study.
An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.
Week by week.
What to expect in the first 8 weeks
- Onset
- 1–7 days
- Peak effect
- 2–4 weeks
- Duration
- 4–12 weeks
Day 1–7Animal
Week one: early hints, for some
Commonly reported: tendon and ligament pain easing within the first one to three weeks, with the first hints for some in week one. BPC-157 speeds repair by growing new blood supply into injured tissue, as it did in rats. How the injury moves and hurts now is the baseline the coming weeks compare with.
The science
In a rat leg starved of blood flow, BPC-157 grew more blood vessels and raised VEGFR2, a receptor that drives vessel growth; in human vessel cells it switched on the Akt–eNOS nitric-oxide pathway (Hsieh 2017). In a dish it sped the migration of rat tendon cells (Chang 2011), and its developers' review ties this blood-vessel effect to better tendon, ligament and bone healing in rats (Seiwerth 2018). No study has timed the first week in people.
Sources- Seiwerth et al. (2018)
- Chang et al. (2011)
- Hsieh et al. (2017)
Updated Sep 2026
Day 7–14Animal
Pain often starts to ease
Commonly reported around weeks one to two: tendon and ligament pain starting to ease. Early changes vary a lot from person to person. New blood vessels growing into the injury bring what repair needs; in rats and in a dish, BPC-157 drove that growth.
The science
In rats, BPC-157 drew blood vessels toward injuries such as a perforated stomach (Sikiric 2018, a review by its developers). Put on burned rat skin, it sped wound closure and raised VEGF, with better granulation tissue and more collagen by day 18; in a dish it made human blood-vessel cells multiply, migrate and form tubes (Huang 2015). The week one-to-two timing comes from user reports; no study has timed it in people.
Sources- Sikiric et al. (2018)
- Huang et al. (2015)
Updated Sep 2026
Day 14–21Animal
Pain often eases by week three
Commonly reported: tendon and ligament pain easing within the first one to three weeks. BPC-157 speeds up the rebuilding of injured tissue; in a rat study where the Achilles tendon was cut from the heel bone, treated tendons healed stronger and better organized over the study's 21 days. How soon an injury can take load again hasn't been studied in people.
The science
Krivic 2006: rats had the Achilles tendon cut from the heel bone and got BPC-157 by daily injection into the abdominal cavity. Checked at days 1, 4, 7, 10, 14 and 21, treated tendons did better on function (the Achilles functional index), strength (load to failure, stiffness) and tissue structure, with better-organized collagen and more type I collagen. The study ended at day 21, so it shows no peak. In a dish, BPC-157 sped the outgrowth and migration of rat tendon cells and helped them survive stress, likely through the FAK–paxillin pathway, but didn't directly make them multiply (Chang 2011). The one-to-three-week timing comes from user reports, not a study.
Sources- Krivic et al. (2006)
- Chang et al. (2011)
Updated Sep 2026
Day 21–28Animal
Many report a calmer gut
Commonly reported: a calmer gut, with less reflux, bloating or irritation, especially when it's taken by mouth. That fits its origin: its developers describe it as coming from a protein in human stomach juice, and in rats it helped injuries of the stomach and gut lining heal. The timing on this card comes from user reports, not a study.
The science
Sikiric 2018, a review by its developers: BPC-157 is described as native to human gastric juice and as an anti-ulcer peptide that heals lesions in rats; after a stomach perforation it drew blood vessels toward the defect. Its developers also propose two-way effects along the gut-brain axis, the background to their rat study in which it protected the hippocampus after the carotid arteries were clamped (Vukojevic 2020); no study has tested that gut-brain link in people. The day 21–28 window comes from user reports.
Sources- Sikiric et al. (2018)
- Vukojevic et al. (2020)
Updated Sep 2026
Day 28–42Animal
The slower part of repair
The quick changes people commonly report come in the first few weeks. What follows is slower: the injured tissue rebuilding and reorganizing, which is harder to feel day to day. The evidence here is from animals: in a rat ligament study, BPC-157 improved healing throughout 90 days.
The science
Vasireddi 2025, a systematic review of 36 studies (35 preclinical, 1 clinical): in animal injury models BPC-157 improved function, structure and strength in muscle, tendon, ligament and bone. One study in its table followed rat knee-ligament (MCL) healing for 90 days, with BPC-157 improving it throughout. The one clinical study was a retrospective of 12 people with knee pain, 7 of whom reported relief lasting over 6 months after a single injection. The slower rebuilding phase on this card is general tendon-healing biology, not a BPC-157 finding.
Sources- Vasireddi et al. (2025)
Updated Sep 2026
Day 42–56Animal
Six weeks in: taking stock
This is where the animal safety data ends: no animal study has checked BPC-157's safety past 6 weeks, and there is no long-term safety data in people. Community runs commonly last 4 to 12 weeks, and many stop once the injury settles. How does the pain compare with day 1?
The science
Vasireddi 2025 (36 studies, searched to June 2024): no animal study assessed adverse events beyond 6 weeks of BPC-157, and none assessed its safety in people. Within 6 weeks, rats and dogs given 6 µg/kg to 20 mg/kg showed no toxic changes in the organs examined. Healing studies do run longer: one followed rat ligament healing for 90 days.
Sources- Vasireddi et al. (2025)
Updated Sep 2026
Any dayCommunity
What BPC-157 is built on
BPC-157 has decades of strong healing research in animals and a long, consistent body of positive community reports. What it does NOT have is human trial data — a 2025 peer-reviewed review found only three tiny uncontrolled studies, all from one investigator, and no rigorous large-scale trial. The animal story is real; the human evidence is thin, and that gap is worth holding honestly.
The science
McGuire et al. 2025 (Curr Rev Musculoskelet Med, Univ. of Utah) is the current anchor: it documents that the only human work is ~16 knee patients, ~12 interstitial-cystitis patients, and 2 IV subjects (≤20mg, no adverse events) — same investigator, no controls — and says the lack of high-quality human trials limits the ability to assess its safety; it also raises a theoretical angiogenesis/tumor caution. Regulatory status: WADA-banned (S0) since 2022; FDA (April 2026) lists it as previously in compounding category 2 and since withdrawn by its nominators, and still cites a possible immune-reaction risk and little or no safety data. No established LD50 in animals; the practical risk signal so far is unregulated production and contamination, not the molecule itself.
Sources- McGuire et al. (2025)
- Vasireddi et al. (2025)
Updated Sep 2026
With TB-500Community
The classic healing combo
A community favorite built on a simple split: BPC-157 works on local repair, new blood supply and tendon healing, while TB-500 helps repair cells move in. Two different jobs toward the same repair. Commonly reported: faster recovery from tendon and ligament injuries.
The science
BPC-157's case is rat work on blood supply and tendon healing; TB-500's is lab and animal work on cell migration, much of it done with the whole thymosin beta-4 protein. Biçer 2026 is the only controlled test of the two together: in 32 rats with cut and repaired Achilles tendons, TB-500 alone significantly raised the load the tendons took before failing and improved their tissue scores, BPC-157 alone trended the same way without reaching significance, and the combination added nothing over either peptide alone.
Sources- Seiwerth et al. (2018)
- Philp et al. (2003)
- Biçer et al. (2026)
Updated Sep 2026
After week 8
Day 84+Community
Past week 12, the data runs thin
Few studies reach this far: one rat study followed ligament healing for 90 days, animal safety studies stop at 6 weeks, and there's no long-term safety data in people. That doesn't mean it's harmful; it means continuing is uncharted, so the call to hold or cycle off is yours, ideally with your clinician.
The science
McGuire 2025: only three pilot studies have looked at BPC-157 in people (knee pain, interstitial cystitis and IV safety), with no adverse effects reported, and rigorous trials are lacking. Vasireddi 2025 found no animal study that assessed adverse events past 6 weeks; healing studies ran longer, one following rat ligament healing for 90 days. McGuire also discusses a theoretical concern that its blood-vessel growth could feed unwanted growth such as tumors, alongside lab findings that point the other way; the concern matters most for open-ended use. There is no evidence-based endpoint past this window.
Sources- McGuire et al. (2025)
- Vasireddi et al. (2025)
Updated Sep 2026
Day 1 is the day you start it.
Extensive animal studies. Human data: three small uncontrolled pilot studies and no controlled trial. Large consistent community reports.
Preliminary research
Mixing and a typical run.
Example numbers
Reconstitution example
Reconstitute a 5 mg vial of BPC-157 with 2 mL of bacteriostatic water and a 350 mcg dose is 14 units on a U-100 syringe, about 14 doses per vial.
- Vial
- 5 mg
- Water
- 2 mL
- Amount
- 350 mcg
Draw to14 units
0.3 mL insulin syringe · 30 units
Run notes
- Cycle
- Typically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- Can be injected any time. Some prefer fasted for systemic effect; near injury site for local repair.
- Routes
- SubQ injection, IM injection, Oral (less studied)
- Stacks
- TB-500, GHK-Cu, Ipamorelin
Safety.
Common side effects
- Nausea (rare)
- Injection site irritation
- Vivid dreams
- Dizziness
Interactions
No published human drug-interaction studies exist for BPC-157 with any medication class (SSRIs, anticoagulants, insulin/antidiabetics, thyroid meds). Animal work has explored interactions with the serotonergic and nitric-oxide systems, but this does not translate to clinical dosing guidance. Its proangiogenic activity is a theoretical consideration in people with a personal/family history of cancer. Discuss any prescription medications with your clinician.
Safety notes
A 2025 peer-reviewed review (McGuire et al., Curr Rev Musculoskelet Med, Univ. of Utah) confirms human evidence is limited to three tiny uncontrolled studies by a single investigator — ~16 knee patients, ~12 interstitial-cystitis patients, and 2 IV subjects (up to 20 mg, no adverse events) — with no controls, and says the lack of high-quality human trials limits the ability to assess its safety in people. Most safety data otherwise comes from rodent and dog studies, where it was well tolerated with no serious toxicity and a very short plasma half-life (~15 min in rats). Community use reports mostly transient injection-site reactions. Note the regulatory status: WADA-banned since 2022 (S0). FDA's compounding list (April 2026) shows BPC-157 as previously in category 2, substances that may pose significant safety risks, and since withdrawn by its nominators; FDA still flags a possible risk of immune reactions to compounded versions and says it has little or no safety information. A theoretical caution worth raising: its proangiogenic activity could in principle support unwanted tissue (e.g. tumor) growth — not observed in the small human data, but uncharacterized. Discuss with your clinician; this is not an approved drug and long-term human safety is unestablished.
Goes with.
In the GLOW stack
Skin & soft-tissue repair stack
In the KLOW stack
GLOW plus KPV — four repair peptides in one vial
In the Wolverine stack
The classic injury repair & recovery stack
With TB-500
In the GH Pulse + Repair stack
Body composition, GH optimization & recovery
With CJC-1295 no DAC and Ipamorelin
In the Shred Stack
Metabolic acceleration & fat loss support
With Tirzepatide and AOD-9604
Compared with.
Questions people ask.
What is BPC-157?
A peptide derived from a protective protein in your stomach. In animal studies it speeds the repair of tendons, ligaments, muscle and gut lining, and it works partly by growing new blood vessels.
How is BPC-157 dosed in research?
The research range for BPC-157 is 200–500 mcg, once or twice daily. Studied in research — not a recommendation.
How long does BPC-157 last?
The half-life of BPC-157 is ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes).
What do people report on BPC-157?
Commonly reported on BPC-157: faster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots.
Is BPC-157 safe?
The research basis for BPC-157 is emerging: primarily preclinical / limited human data. Common side effects in the library: nausea (rare), injection site irritation, vivid dreams and dizziness.
What does BPC-157 stack with?
Common stacks for BPC-157: TB-500, GHK-Cu and Ipamorelin. Curated stacks with BPC-157: GLOW, KLOW, Wolverine, GH Pulse + Repair and Shred Stack.
Reference.
- Cadence
1–2× daily
Once or twice daily
- Half-life
~4–6 hours
~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes)
- Research basis
●
●●EmergingPrimarily preclinical / limited human data
PepVault for iPhone
Track BPC-157 in PepVault
Log every dose, keep your vial and the doses left in it and watch its estimated active level. 7 days free on the yearly plan for new subscribers.
Open the calculatorHow the vial count worksExplore the live demo
Reviewed How we check the library